Clinical Trial Results:
Add-on therapy with low dose fenfluramine in Lennox Gastaut epilepsy
Summary
|
|
EudraCT number |
2015-004008-46 |
Trial protocol |
BE |
Global end of trial date |
19 Jul 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Jan 2025
|
First version publication date |
30 Jan 2025
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
FFA-LGS
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
UZ Leuven
|
||
Sponsor organisation address |
Herestraat 49, Leuven, Belgium, 3000
|
||
Public contact |
Lieven Lagae, UZ Leuven, lieven.lagae@uzleuven.be
|
||
Scientific contact |
Lieven Lagae, UZ Leuven, lieven.lagae@uzleuven.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Jan 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
01 Jan 2018
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
19 Jul 2024
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To study the potential effect of add-on fenfluramine in refractory Lennox Gastaut epilepsy. ( exploratory dose finding add-on trial).
- Dose finding study add on low dose FFA (0,2 or 0,4 or 0,8 mg/kg/day, max 30 mg/day)
- Number of responders at each dosage (responder : min 50 % decrease of nr of seizures per 4 weeks compared to baseline period)
- Safety of low dose FFA
|
||
Protection of trial subjects |
To minimize stress and pain during blood collections in pediatric study subjects, a combination of psychological and physical strategies is employed. Distraction techniques such as cartoons, toys, or virtual reality headsets help divert the child’s attention, reducing anxiety and perceived discomfort. Topical anesthetics, like numbing creams or sprays, are applied to the skin to desensitize the area before needle insertion. For added comfort, vibrating cold pads or other pain-relief devices may be used near the site to confuse nerve signals and further reduce pain. Staff are trained to use gentle, child-centered communication to reassure and guide the child through the procedure, and allowing parents to be present provides an additional layer of emotional support. These methods collectively ensure that blood collection is as stress-free and painless as possible.
To avoid stress during other assessments such as ECG, echo and collection of vital signs, we made sure the communication was gentle and child-centered and that
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
22 Mar 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 13
|
||
Worldwide total number of subjects |
13
|
||
EEA total number of subjects |
13
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
7
|
||
Adolescents (12-17 years) |
6
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
The first patient was recruited on 22 MAR 2016 and the last patient on 20 JUL 2016. A phase 3 study was initiated during this trial and therefore the recruitment officially ended on 6 OCT 2017. The last follow-up visit of the remaining subjects took place in JUL 2024. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
1. Electro-clinical epilepsy syndrome compatible with Lennox Gastaut syndrome 2. Drug resistant: at least 4 documented seizures in the last 4 weeks before inclusion 3. Age between 3 and 18 years All the subjects that were screened were enrolled in the study. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Baseline period
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Blinding implementation details |
Not blinded.
|
||||||||||||||||||
Arms
|
|||||||||||||||||||
Arm title
|
Baseline | ||||||||||||||||||
Arm description |
- | ||||||||||||||||||
Arm type |
no intervention | ||||||||||||||||||
Investigational medicinal product name |
No product
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Anticoagulant and preservative solution for blood
|
||||||||||||||||||
Routes of administration |
Auricular use
|
||||||||||||||||||
Dosage and administration details |
No product
|
||||||||||||||||||
|
|||||||||||||||||||
Period 2
|
|||||||||||||||||||
Period 2 title |
Overall trial
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Arm title
|
IMP dosing | ||||||||||||||||||
Arm description |
Dosing IMP: starting dosage 0.2 mg/kg/day BID; second step: 0.4 mg/kg/day BID; max dosage 0.8 mg/kg/day BID or 30 mg/day BID. Review of epileptic seizures is performed on each milestone and IMP dose increases if subject is non-responder (< 50% reduction of total number of clinically observable seizures with a motor component (GTC or/and TS or/and AS or/and M or/and FS) compared to baseline). | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Fenfluramine
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Syrup
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Oral solution of fenfluramine (2.5 mg/mL)
Dosage: starting dosage 0.2 mg/kg/day BID; second step: 0.4 mg/kg/day BID; max dosage 0.8 mg/kg/day BID or 30 mg/day BID
|
||||||||||||||||||
|
|||||||||||||||||||
Period 3
|
|||||||||||||||||||
Period 3 title |
Extension period
|
||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||
Allocation method |
Not applicable
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Arm title
|
Dosing IMP | ||||||||||||||||||
Arm description |
Dosing IMP: continuing at IMP dose of end of overall study period (0.2 mg/kg/day BID, 0.4 mg/kg/day BID or 0.8 mg/kg/day BID (max 30 mg/day BID)). Review of epileptic seizures is performed every 3 month. If subject is non-responder (< 50% reduction of total number of clinically observable seizures with a motor component (GTC or/and TS or/and AS or/and M or/and FS) compared to baseline), subjects are excluded from the study. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Fenfluramine
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Syrup
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Oral solution of fenfluramine (2.5 mg/mL)
Continuation of dose of overall study period (0.2 mg/kg/day BID, 0.4 mg/kg/day BID or max dosage 0.8 mg/kg/day BID or 30 mg/day BID)
|
||||||||||||||||||
|
|||||||||||||||||||
Notes [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: 1 subject completed the overall study but chose to not enter the extension period. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline period
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Collecting baseline seizure frequency for each subject for 4 weeks. This number will be used to compare the seizure frequency with in the next phase of the trial. Drug regimen will remain stable during baseline. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Baseline
|
||
Reporting group description |
- | ||
Reporting group title |
IMP dosing
|
||
Reporting group description |
Dosing IMP: starting dosage 0.2 mg/kg/day BID; second step: 0.4 mg/kg/day BID; max dosage 0.8 mg/kg/day BID or 30 mg/day BID. Review of epileptic seizures is performed on each milestone and IMP dose increases if subject is non-responder (< 50% reduction of total number of clinically observable seizures with a motor component (GTC or/and TS or/and AS or/and M or/and FS) compared to baseline). | ||
Reporting group title |
Dosing IMP
|
||
Reporting group description |
Dosing IMP: continuing at IMP dose of end of overall study period (0.2 mg/kg/day BID, 0.4 mg/kg/day BID or 0.8 mg/kg/day BID (max 30 mg/day BID)). Review of epileptic seizures is performed every 3 month. If subject is non-responder (< 50% reduction of total number of clinically observable seizures with a motor component (GTC or/and TS or/and AS or/and M or/and FS) compared to baseline), subjects are excluded from the study. |
|
|||||||
End point title |
≥50% reduction in median CS frequency [1] | ||||||
End point description |
|||||||
End point type |
Primary
|
||||||
End point timeframe |
In the 20 weeks of IMP treatment.
|
||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No specific statistical analyses are used, except for medians and percentages. |
|||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Convulsive seizure frequency per month at the last visit | ||||||||
End point description |
Median seizure frequency at the last visit for the intent‐to‐treat study population (N = 13)
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Seizure frequency at the last visit
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Reduction in convulsive seizure frequency | ||||||
End point description |
|||||||
End point type |
Secondary
|
||||||
End point timeframe |
Median reduction seizure frequency at the last visit compared with baseline for the intent‐to‐treat study population.
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Convulsive seizure frequency per month at the last visit in patients who completed 20 weeks of IMP treatment | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Mean reduction in convulsive seizure frequency at the last visit compared to the baseline in the patients who completed 20 weeks of IMP treatment.
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Reduction of convulsive seizures at the last visit in patients who completed 20 weeks of IMP treatment | ||||||
End point description |
|||||||
End point type |
Secondary
|
||||||
End point timeframe |
The value of the last visit in patients who completed 20 weeks of IMP treatment was compared with baseline.
|
||||||
|
|||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Possibly related adverse event reported from baseline period, the overall study and extension period until 15 months.
|
||||||||||||||||||||||||||||
Adverse event reporting additional description |
Adverse events were reported during every visit and self-reporting by participants
|
||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||
Dictionary name |
UZ Leuven guidelines | ||||||||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||
Reporting group title |
Fenfluramin
|
||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
19 Jan 2016 |
Adding template of epileptic seizure diary. |
||
08 Mar 2016 |
- Adding recruitment letter to send to potential families.
- Adding Sub-I.
- Updated investigator brouchure.
- Adjustments to the protocol:
- Adding information on how to deal with subjects with reproductive potential (adding pregnancy tests, information on sperm and egg donation and contraception use,...)
- Adding prohibited food consumptions (grapefruit and seville oranges)
- Adding prohibited concomitant medication (felbamate, drugs that interact with central serotonin and drugs that potentially interact with fenfluramin via CYP2D6, CYP3A4 and/or CYP2B6 pathways) |
||
25 Aug 2017 |
Changes to the protocol:
- Adding information on not completing ICF's on subjects that become 18 years during the clinical study since they are mentally not capable to.
- Adding information on changing the IMP dose in case of adverse events
- Adding the possibility on continuing IMP dosing when the subject is a non-responder but has an effect on the severity and/or duration of the epileptic seizures.
- Adding the possibility to change the IMP dose in the extension phase regardless of the fact that the subject is a responder or not.
- Adding the possibility for non-responder subjects to enter the extension phase
- Updating the flowchart for the extension phase so that safety blood samples, blood AED levels and cardiac evaluation are not necessary each visit. |
||
24 Apr 2018 |
Clarifications in the study protocol:
- On each on site visit the convulsive seizures are counted starting 28 days before the on site study visit.
- Frequency of cardiologic assessments (ECG and echo) and blood collections in the extension period are performed at descretion of the PI but once a year at minimum.
- AED levels are determined in the standard of care clinical follow-up.
- Visit window of extension phase study visit is 3 months +/- 2 weeks.
- Harmonizing seizure type abbreviations.
- Dose adjustments during the extension phase are respons/effect dependant with a dose of minimum 0.1 mg/kg/day and a maximum of 30 mg/day. Reasons for dose adjustments need to be document in the source documents and CRF. |
||
09 Aug 2019 |
As part of the European General Data Protection Regulation (GDPR), which has been in force since May 2018, an information letter will be prepared to inform (by phone and/or email) study patients, who are still participating in the study after May 2018, how their personal data will be managed, stored and used. |
||
13 Feb 2020 |
New version of investigator brochure. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
This study is limited by the small sample size and lack of a placebo control group. | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/30146701 |